Showing posts with label SWOT analyses. Show all posts
Showing posts with label SWOT analyses. Show all posts

ReportsandReports - The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses



The Eastern European pharmaceutical companies comprise both Eastern Europe-based and MNCs. This chapter provides an insight into the current state of Eastern European pharmaceutical industry as well as the evolving trends. It also provides the competitive landscape of the industry based on financial and operational (revenue growth over the last five years, exposure to major markets and presence in major therapeutic areas) parameters in the Eastern European region.

The report also includes profiles of the top ten companies in the region and also gives a brief summary of top 11 to 20 players. The top 10 companies in the Eastern European pharmaceutical industry were assessed on following parameters:
  • Each company’s market share in the Eastern European pharmaceutical market;
  • Each company’s marketed products, geographic and  therapeutic focus;
  • Each company’s growth strategies and major acquisitions and divestments in this market;
  • Key mergers and acquisitions formed by these companies;
  • Business-related strengths and weaknesses of these companies, and insights into the opportunities and threats facing them.
Key features of this report
  • Market dynamics of the Eastern European pharmaceutical market during the period 2004-08.
  • Key market drivers and resistors.
  • Trends of the Eastern European pharmaceutical market.
  • Identification of the top 10 players in the Eastern European pharmaceutical market .
  • Company analysis and market share of the top 10 players in the Eastern European pharmaceutical market.
Scope of this report
  • Learn from the strategies of the Eastern European pharmaceutical companies to target future growth markets effectively, avoid their mistakes, replicate their successes and learn of the threats they face.
  • Benchmark your performance against the leading Eastern European pharmaceutical companies using market share data by company and comprehending their strategies.
  • Understand the major issues affecting the Eastern European pharmaceutical market.
  • Predict the key growth areas in the Eastern European pharmaceuticals market arising from the government’s initiative to promote generics in the region.
Key Market Issues
  • Parallel trade: Increasing incidence of parallel traded products will impact companies operating in the region resulting in potential loss of sales eventually affecting cash flows and bringing down innovation in drug development.
  • Complex pricing: Complex drug pricing, reimbursement and purchasing policies will affect the development of new drugs thus affecting the growth of Eastern European pharmaceutical market.
  • Insufficient funds: Inadequate funding from the government may slowdown the development of the pharmaceutical industry in Eastern Europe.
  • Regulatory hurdles: Increasing due diligence and compliance with standards leads to cost overrun and delay in new product launches.
Key findings from this report
  • The Eastern European market is valued at $25,417m as of 2008, which is an increase of 19.9% over 2007. The industry witnessed a CAGR of 19.6% during 2004–08.
  • Poland, Russia and Hungary lead the Eastern European pharmaceutical market and together contributed 62.1% of total market value in 2008.
  • Novartis lead the Eastern European pharmaceutical market with a market share of 7.1% in 2008, followed by Sanofi-Aventis (6.1%) and GSK (4.9%).
  • Parallel trade in Eastern Europe plays an important role influencing the multi-nationals’ branded products, which results in potential loss of sales and brings down the activity of innovative drug development.
Key questions answered
  • What was the market size of the Eastern European pharmaceutical market in 2008?
  • What are the trends in the Eastern European pharmaceutical market?
  • Who are the top 10 players in the market?
  • What is the market share of each of the companies?
  • What are the growth strategies of the top 10 companies?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |

ReportsandReports - The Top 10 Cardiovascular Device Companies: Market trends, growth strategies, and SWOT analyses



The cardiovascular (CV) device industry is highly competitive and has reached maturity resulting in single digit growth rates of prominent devices such as pacemakers, defibrillators, and drug eluting stents (DES). Innovations in niche sectors such as atrial fibrillation (AF) and ventricular assist devices (VADs) are poised for double digit growth in the near to mid-term future. From 2007–09, the top three companies in the CV segment acquired other smaller firms to expand their product portfolios and to gain market share in new geographies. Some major companies also established manufacturing facilities outside the US to enhance cost containment and product distribution. The CV device market remained relatively resilient during the economic downturn compared with other healthcare segments. The 2007–09 period also witnessed a considerable rise in consolidation activities among major companies.
This report provides detailed profiles of the top 10 cardiovascular (CV) device companies and brief profiles of other major players. It also elucidates trends within the cardiovascular device market. The detailed profiles contain descriptions of business, financial performance, growth strategies and SWOT analyses.

The analysis is based on:
  • Each company’s consolidated and segmental financial performance;
  • Each company’s growth strategies and major acquisitions and divestments relating to the CV devices market;
  • Key partnerships and alliances formed by these companies;
  • Business-related strengths and weaknesses of these companies and insights into the opportunities and threats facing them.
Key features of this report
Drivers
  • Innovations in CRM and DES segments such as MRI compatible pacemakers from Medtronic and Abbott’s Xience drug eluting stent with their positive clinical outcomes support stronger evidence for long-term benefits.
  • Emerging markets for DES in Canada, China and parts of Asia furnish opportunities to expand businesses for CV companies.
  • Ageing population in industrialized markets such as the US, Europe and Japan are increasing. Moreover, the ICDs and pacemakers in these geographies are expected to have a second-phase of CRM implants.
Resistors
  • The safety and efficacy of DES are under scrutiny following numerous clinical studies and more studies are being executed to justify the long-term efficacy of DES intervention.
  • Markets for ICDs and pacemakers have reached maturation. ICD sales are growing between 4-5% and pacemakers between 2-3% annually.
  • Reduction in reimbursement affects sales and profitability for CV device manufacturers.
Scope of this report
  • Learn from the business operation strategies of the premier CV device companies to target future growth markets effectively, avoid their mistakes, and replicate their successes.
  • Benchmark your performance against the leading CV device companies.
  • Analyze the growth strategies of major players in the CV industry and how their business models are planned for the next 3 to 5 years.
  • Compare performances of the top 10 companies in the CV market with respect to acquisitions, new product innovation, geographic expansion, and industry challenges.
  • Save time, money and resources on analyzing the performance of leading CV device companies using this report.
Key Market Issues

Pricing pressures due to industry regulations

The CV device industry is highly regulated around the world with stringent guidelines defined by regulatory bodies. The medical device approvals by governing bodies such as the FDA in the US have become very meticulous that CV device manufacturers are launching products outside the US such as Europe and Canada. Since the prices are strictly regulated outside the US, manufacturers will be forced to launch their products in the US for a similar price. In the long run, the pricing pressures would continue to prevail and limit the profitability margins for CV device manufacturers.

Significance of CV device innovation

Markets reaching saturation for major revenue generators in the CV device segment such as ICD, pacemaker and DES. New device innovation will be the only parameter that will assure a company of its competitive edge. Novel technologies that are uncontested would help a company by allowing it to charge premium pricing. Research & development (R&D) initiatives and interdisciplinary knowledge will remain the benchmark for assuring a company’s success and commanding prevalence in the market.
Decline in capital expenditure of hospitals

In the US, hospitals spend a considerable amount of their revenues on capital expenditure to improve their facilities and purchase new medical technology. However, the impact of economic recession since 2008 had forced hospitals to decrease their capital expenditure by almost 6%. This decline will impact the medical devices industry across all sectors in the CV device division. Some segments of the CV device industry such as ICD, pacemakers, heart valves and stents will remain insulated from the economic impact given their non-elective nature of associated procedures. other low budget, high-frequency CV accessories that hospitals purchases on a regular basis will be affected due to decline of capital expenditures.

Key findings from this report
  • The top 10 companies had cumulative revenues of $27bn in 2009 and over 95% share of the global CV device market. The top 3 CV device companies dominate more than 60% of this segment’s market share.
  • Medtronic was the No. 1 company with CV device revenues of $8.6bn in 2009. The company strategically acquired other franchises to expand its heart valve and catheter product portfolios.
  • The growth rates of the implantable cardioverter defibrillator (ICD) and pacemaker sectors in 2009 were 4–5% and 2–3% respectively. The ventricular assist device (VAD) and atrial fibrillation (AF) sectors are poised for double-digit growth rates over the next 2–3 years.
  • Business Insights’ analysis revealed that, even during economic recession, the CV device market has remained buoyant, achieving single-digit growth. However, the growth rate in this segment – with the exception of AF solutions and VAD sales – will remain in the mid single digits over the next decade.
Key questions answered
  • What was the market value of the global CV device industry in 2009?
  • What are the global market values for the major CV device segments?
  • What are the key trends in the CV device industry and what are the leading companies’ strategic responses?
  • Who are the major players in the global CV device market?
  • What are the growth strategies of the leading CV device companies?
About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser’s URL address field. Remove the space if one exists.)

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Read More
Posted by Unknown on
categories: , , , , , , , , |

The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses now available at ReportsandReports

Dallas, TX: ReportsandReports announce The Top 10 Eastern European Pharmaceutical Companies: Growth strategies, performance and SWOT analyses Market Research Report in its Store.


The Eastern European pharmaceutical companies comprise both Eastern Europe-based and MNCs. This chapter provides an insight into the current state of Eastern European pharmaceutical industry as well as the evolving trends. It also provides the competitive landscape of the industry based on financial and operational (revenue growth over the last five years, exposure to major markets and presence in major therapeutic areas) parameters in the Eastern European region.

Table of Contents
Chapter 1 Introduction
What is this report about?
Methodology
Chapter 2 Industry overview
Summary
Introduction
Market dynamics
Eastern European market: size and growth
Parallel trade in Eastern Europe
Key market drivers and resistors
Competitive landscape
Competitive position of the top 10 companies
Comparative analysis of the top 10 companies
Trends
Consolidation underway
Increasing use of generics
Rise of value added generics and biosimilars
Cancer market represents strong commercial opportunity
Increasing presence of biotechnology
Chapter 3 Novartis
Summary
Company overview
Geographic focus
Marketed products
Therapeutic focus
Research and development
Growth strategies
Focus on biosimilars
Strengthening its oncology portfolio
Strengthening presence in Romania
Growing business by forging alliances and partnerships
Acquisitions and divestments
SWOT analysis
Chapter 4 Sanofi-Aventis
Summary
Company overview
Geographic focus
Marketed products
Therapeutic focus
Research and development
Growth strategies
Focusing on external collaborations for business development
Acquisitions and divestments
SWOT analysis
Chapter 5 GSK
Summary
Company overview
Geographic focus
Marketed products
Therapeutic focus
Research and development
Growth strategies
Investing in product capabilities and R&D
Partnerships fostering growth
Expanding product portfolio through new drug launches
Acquisitions and divestments
SWOT analysis
Chapter 6 Servier
Summary
Company overview
Geographic focus
Marketed products
Therapeutic focus








About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact: 
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Read More
Posted by Unknown on
categories: , , , , , , , , , |

The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses now available at ReportsandReports

Dallas, TX: ReportsandReports announce The Top 10 Pharmaceutical Companies in India: Growth strategies, performance and SWOT analyses Market Research Report in its Store.


The leading players in the Indian pharmaceutical market comprise both India-based and MNCs. This report provides an insight to the current state of Indian pharmaceutical industry as well as the evolving trends. This report analyzes the Indian pharmaceutical industry in light of market size, key drivers and resistors, trends and competitive positioning in the global market. It also analyzes the competitive landscape of the industry based on financial and operational (field force strength, R&D spend, exposure to chronic therapeutic areas and the US pharmaceutical market) parameters.

Table of Contents
Chapter 1 Introduction 20
What is this report about? 20
Methodology 20
Chapter 2 Industry overview 24
Summary 24
Introduction 25
Market dynamics 25
Indian pharmaceutical market: size and growth 25
Key market drivers and resistors 26
India’s adoption of product patent regime 27
Evolution of biopharmaceuticals in India 28
Competitive positioning of India in global pharmaceutical market 30
Competitive landscape 32
Competitive positioning of the top 10 companies 32
Exposure to US generics market 35
Comparative analysis of the top 10 companies 36
Trends 37
Increasing participation of innovator companies in Indian pharmaceutical space 37
Pharmaceutical companies making inroads into rural India 38
Shifting focus towards Japanese generics market 39
Growing prevalence of lifestyle diseases 40
Expanding alliances in biopharmaceuticals 41
Chapter 3 Cipla 46
Summary 46
Company overview 47
Marketed products 47
Therapeutic focus 49
Research and development 49
Growth strategies 50
Expanding in international markets through alliances and partnerships 50
Expanding capabilities 50
Growing in the US generics market 51
Acquisitions and divestments 51
SWOT analysis 52
Chapter 4 Ranbaxy 54
Summary 54
Company overview 55
Marketed products 56
Therapeutic focus 56
Research and development 57
Growth strategies 58
Rebuilding business in the US market 58
Shifting focus towards complex products in the US 58
Monetizing the FTF opportunities in the US 58
Improving penetration in emerging markets 59
Strengthening management involvement in Ranbaxy 59
Acquisitions and divestments 60
SWOT analysis 61
Chapter 5 GSK (India) 64
Summary 64
Company overview 65
Marketed products 66
Therapeutic focus 66
Research and development 67
Growth strategies 68
Augmenting product portfolio in India 68
Leveraging its parent company’s product portfolio 68
In-licensing products 69
Expanding rural presence and hospital sales 69
Acquisitions and divestments 70
SWOT analysis 71
Chapter 6 Piramal Healthcare 74
Summary 74
Company overview 75
Marketed products 75
Therapeutic focus 77
Research and development 77
Growth strategies 78
Capitalize on contract manufacturing opportunities 78
Growing business through alliances and partnerships 78
Acquisitions and divestments 79
SWOT analysis 81
Chapter 7 Zydus Cadila 84
Summary 84
Company overview 85
Marketed products 86
Therapeutic focus 86
Research and development 87
Growth strategies 88
Alliances fostering growth in international generics markets 88
Sustaining revenue growth in Indian formulation business 89








About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact: 
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Read More
Posted by Unknown on
categories: , , , , , , , , |

The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses now available at ReportsandReports

Dallas, TX: ReportsandReports announce The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses Market Research Report in its Store.


Biologics continue to outperform the global Parma market, driven by premium priced therapies for conditions that cannot be managed by conventional drugs. The rapid penetration of novel biologics and the gradual expiry of their patents will create significant market opportunities for biosimilars developers through to 2016. In the short term, biosimilar market growth will be driven by drug classes including erythropoietin, filgrastim, human growth hormone (hGH) and insulin. ‘The Top 10 Biosimilars Players: Positioning, performance and SWOT analyses’ is a report published by Business Insights that examines the competitive landscape of the global biosimilars industry. The latest key issues and evolving business models in the biosimilars market are identified and the leading companies in this sector are profiled in detail. This report examines the portfolio sales performances, pipelines and growth strategies of each of the top 10 biosimilars companies. The opportunities and threats facing each of these leading players are also assessed. This report also examines the size, growth and major trends of the global biosimilars industry, in addition to providing to an assessment of leading biosimilars companies outside of the top 10.








About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact: 
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/

Read More
Posted by Unknown on
categories: , , , , , , , , , , |